

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		10/091,357	PILLARISETTI, SIVARAM	
Examiner		Art Unit	Maher M. Haddad	
		1644	Page 1 of 1	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,306,613	10-2001	Florkiewicz et al.	-----
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ettenson et al Endothelial heparan sulfate is necessary but not sufficient for control of vascular smooth muscle cell growth. J Cell Physiol. 2000 Jul;184(1):93-100.
	V	Paka et al Perlecan, Heparan sulfate proteoglycan, mediates the anti-proliferative effect of apolipoprotein E:An underlying mechanism for the modulation of smooth muscle cell growth? Circulation (Nov. 2 1999) Vol. 100, No. 18, Suppl. pp.I.548, Ab # 2886
	W	Obunike et al. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):111-8.
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.